Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/TransMedics reports Q1 2026 revenue up 21%, net income $7.3M, and confirms 2026 revenue guidance of $727-$757M.
TMDX
$76.00
+$0.52 +0.69%

TransMedics reports Q1 2026 revenue up 21%, net income $7.3M, and confirms 2026 revenue guidance of $727-$757M.

Company Fundamentals
05 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

TransMedics Group announced a 21% increase in Q1 2026 revenue to $173.9 million and net income of $7.3 million, driven by higher use of its Organ Care System and logistics services. Despite increased operating expenses and lower operating margins due to investments in growth and supply chain costs, the company reaffirmed its full-year 2026 revenue guidance of $727 million to $757 million, expecting 20-25% growth. TransMedics is focused on expanding its heart and lung transplant programs in the U.S. and Europe and advancing its kidney transplant technology to drive future growth and improve access to organ transplants globally.

More News (TMDX)

Law firm investigates TransMedics after margin pressure and investment disclosures hurt stock price

Law firm investigates TransMedics after margin pressure and investment disclosures hurt stock price

Johnson Fistel, PLLP is investigating TransMedics Group, Inc. following the company's Q1 2026 financial report that showed declining operating margins and increased expenses due to investments in growth and supply chain costs. Despite revenue growth,...

Market News
Bearish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App